scholarly journals Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non-Hodgkin Lymphoma: Effect of Histological Grade and Follicular International Prognostic Index

2008 ◽  
Vol 14 (1) ◽  
pp. 36-42 ◽  
Author(s):  
Julie M. Vose ◽  
Philip J. Bierman ◽  
Fausto R. Loberiza ◽  
James C. Lynch ◽  
Gregory R. Bociek ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Autologous Stem Cell Transplantation ◽  
Histological Grade ◽  
International Prognostic Index ◽  
Prognostic Index ◽  
Long Term Outcomes ◽  
Non Hodgkin Lymphoma

Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3423-3423
Author(s):  
Amrita Krishnan ◽  
Andrew Raubitschek ◽  
Joycelynne Palmer ◽  
Auayporn P. Nademanee ◽  
N. Kogut ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
High Dose ◽  
Poor Risk ◽  
Non Hodgkin Lymphoma ◽  
The Impact

Abstract Abstract 3423 Poster Board III-311 Long term survival for patients with chemo-refractory non-Hodgkin lymphoma (NHL) is poor even with high dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Strategies such as novel transplant conditioning regimens and post transplant maintenance therapy are being evaluated to improve outcomes. Herein we report on the results of a phase II study designed to assess the impact of a novel radioimmunotherapy (RIT) based conditioning regimen of Y90 ibritumomab tiuxetan in conjunction with high dose BEAM (BCNU, Etoposide, Ara–C, Melphalan) in patients with poor risk NHL. Between May 2002 and Jan 2009, 31 patients who were either primary induction failure (n=18) or in partial remission (n=13) underwent HDC with Y90 plus BEAM. Patients received an imaging dose of Indium 111 on day -21 followed by a treatment dose of Y90 (0.4mCi/kg) on day-14. HDC with BEAM was started on day -7. The median age at ASCT was 57 (range: 19–70). The majority of patients were male (n=23, 74%) and had advanced stage disease (III or IV) at the time of diagnosis, (n=23, 74%). The histologies included Follicular n=6, Diffuse Large B-cell n=13, Mantle cell n=8, and Transformed n=4. The median number of prior regimens was 2 (range: 1-5). All patients engrafted at a median of 11 days. At the time of analysis, 23 (74%) patients were alive, and eight had expired (seven due to relapse/progressive disease, one due to COPD). The non-relapse mortality was 3.2%. The median length of follow-up for surviving patients is 46.9 months (range: 3.3-75.0). The two-year overall survival and disease-free survival was 77.9% (95%CI: 62.7-87.6%) and 50.9% (95%CI: 40.5-60.3%) respectively for the entire cohort. However, the relapse rate in the subset of MCL pts was strikingly high and approached 80% at 4 yrs. The other subgroups had a stable DFS (figure 1). In conclusion in this poor risk group of patients Y90 plus high dose BEAM can induce responses and long term remissions, however, for patients with chemorefractory MCL other treatment approaches may be warranted. Disclosures Off Label Use: yttrium 90 in combination with high dose BEAM chemotherapy.

Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma

2016 ◽  
Vol 95 (7) ◽  
pp. 1121-1128 ◽  
Author(s):  
Karin Hohloch ◽  
Samira Zeynalova ◽  
Björn Chapuy ◽  
Michael Pfreundschuh ◽  
Markus Loeffler ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Non Hodgkin Lymphoma

scholarly journals Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation

2007 ◽  
Vol 40 (8) ◽  
pp. 741-746 ◽  
Author(s):  
T N Trahair ◽  
M R Vowels ◽  
K Johnston ◽  
R J Cohn ◽  
S J Russell ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Long Term Outcomes

scholarly journals Correction: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation

2019 ◽  
Vol 121 (10) ◽  
pp. 894-895 ◽  
Author(s):  
Frank Berthold ◽  
Angela Ernst ◽  
Barbara Hero ◽  
Thomas Klingebiel ◽  
Bernhard Kremens ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
High Dose Chemotherapy ◽  
Oral Chemotherapy ◽  
High Dose ◽  
Long Term Outcomes

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Sign in / Sign up

Export Citation Format

Share Document